Quotient Ltd
Quotient Ltd (QTNT): 2 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.5 months
D/E -1.57 · 5% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for Quotient Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$11.9M
Quarterly Burn
$25.0M
Runway
2.5 mo
Revenue
$10.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| mosaiq | Preclinical |
| sonishield 100 antimicrobial ultrasound gel | — |
Frequently asked questions
How many drug candidates are in Quotient Ltd's pipeline?
Quotient Ltd (QTNT) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Quotient Ltd's lead drug candidate?
Quotient Ltd's most advanced tracked candidate is mosaiq (Preclinical) for blood grouping and disease screening.
What is Quotient Ltd's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Quotient Ltd has approximately 2.5 months of cash runway.
Who is the CEO of Quotient Ltd?
The Board is the chief executive officer of Quotient Ltd (QTNT).
Get the full picture on Quotient Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.